Jane Street’s Oramed Pharmaceuticals ORMP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$53.2K Buy
+11,400
New +$51.5K ﹤0.01% 10938
2022
Q4
– Sell
-78,100
Closed -$506K – 9849
2022
Q3
$506K Buy
78,100
+65,400
+515% +$529K ﹤0.01% 6675
2022
Q2
$58K Sell
12,700
-28,800
-69% -$154K ﹤0.01% 8880
2022
Q1
$359K Sell
41,500
-52,800
-56% -$541K ﹤0.01% 8084
2021
Q4
$1.35M Sell
94,300
-18,000
-16% -$376K ﹤0.01% 5306
2021
Q3
$2.47M Buy
+112,300
New +$1.91M ﹤0.01% 4042

Other funds holding ORMP

Jane Street's ORMP Position: Q3 2026 in Review

Jane Street reduced its Oramed Pharmaceuticals (ORMP) stake by 76% in Q3 2026, selling an estimated $390K and leaving 27,068 shares worth $126K. The position accounts for ﹤0.01% of the portfolio, ranked #10434.

Jane Street first reported a position in ORMP in Q1 2014 and has held it in 29 quarters since. The position peaked at $1.6M in Q4 2022. 93 funds tracked by Wall St. Rank hold ORMP as of Q3 2026.

  • Jane Street held 27,068 shares of Oramed Pharmaceuticals worth $126K as of Q3 2026.
  • Jane Street sold 86,281 Oramed Pharmaceuticals shares in Q3 2026, an estimated $390K.
  • Oramed Pharmaceuticals made up ﹤0.01% of Jane Street's portfolio in Q3 2026, its #10434 holding.
  • Jane Street first reported a position in Oramed Pharmaceuticals in Q1 2014 and has held it in 29 quarters since.
  • Jane Street's Oramed Pharmaceuticals position peaked at $1.6M in Q4 2022.
  • 93 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2026.

Based on Jane Street's 13F filing for Q3 2026, filed 12 Nov 2026.